Overview

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Kanisa Pharmaceuticals

Treatments:

Cytarabine
Daunorubicin